# Filing Detail

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0000950170-24-049172
Filing Date
2024-04-26
Accepted
2024-04-26 16:20:04
Documents
3

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFA14A | antx-defa14a-2023_.htm | DEFA14A | 15986
2 | GRAPHIC | img169789561_0.jpg | GRAPHIC | 1262528
3 | GRAPHIC | img169789561_1.jpg | GRAPHIC | 50829
| Complete submission text file | 0000950170-24-049172.txt |  | 1824369

Mailing Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027
Business Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027 (650) 331-9090
AN2 Therapeutics, Inc. (Filer) CIK: 0001880438 (see all company filings)

EIN.: 820606654 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-41331 | Film No.: 24884085
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)